My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
February 2011
Patient Care and Science
NIAID Seeks Input on ID Clinical Trials Network

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking input from the ID community on the research agenda for a planned infectious diseases (non-HIV/AIDS) clinical trials infrastructure that leverages the successes of its existing HIV/AIDS Clinical Trials Networks.

As part of the new infrastructure, a new ID Leadership Group will be competitively selected to design and implement these trials, which will focus primarily on bacterial antibiotic resistance. The Leadership Group will also have the additional capability of responding rapidly to emerging infectious diseases such as an outbreak of SARS or pandemic influenza (see related NIAID blog post).

In early 2012, NIAID plans to issue a request for applications (RFA) from scientific investigators who are interested in forming the new ID Leadership Group. The establishment of clinical trial sites will be the subject of a subsequent funding opportunity a year later.

NIAID is requesting written comments by April 4 with input regarding a clinical research agenda for the Leadership Group. Click here for more information. NIAID is also hosting a March 7 public town hall meeting in Bethesda, Md., to solicit input. IDSA will submit written comments, and John G. Bartlett, MD, FIDSA, will represent the Society at the meeting. During the meeting, NIAID will describe and respond to questions on the plans for the non-HIV/AIDS infectious diseases network. The meeting will not be webcast, but the meeting summary and presentations will be posted online afterward.

Additionally, NIAID is planning to expand the focus of its existing HIV/AIDS Clinical Trials Networks to include AIDS co-morbidities. Tuberculosis, hepatitis B, and hepatitis C will fall under research conducted by the HIV/AIDS Leadership Groups. NIAID held a town hall meeting and received comments on the HIV/AIDS network last fall (see "The Future of the NIAID Clinical Trials Networks").
How useful is this article?

Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
NIAID Seeks Input on ID Clinical Trials Network
EIN Update: Antimicrobial Prophylaxis and Neurosurgical Procedures
U.S. Supreme Court Upholds Vaccine Injury Compensation Program
ACIP Urges Pertussis Vaccination for Health Care Workers
Drug Approvals, Recalls, Adverse Events Update
2011 Immunization Schedules Now Online
Clinical Practice Management
Electronic Health Records and “Meaningful Use” Incentives
“Ask the Coder” Answers CPT Questions
Physician Compensation Survey Now Available
Global ID
Science Speaks Blog to Host Series on Medical Male Circumcision
What Lies Ahead for Global AIDS and TB: A Discussion with Gates Foundation Leaders
Policy and Advocacy
President’s FY 2012 Budget Strengthens ID Programs
IDSA Weighs in on Health Care Reform Provisions
Your Colleagues
Call for Nominations for the 2011 IDSA Election
Members on the Move
Welcome, New Members!
Education & Resources
IDSA Influenza Conference Available Online, with CME Credit
Antimicrobial Resistance CME Activity Available Online
Sign Up for Alerts for IDSA Journals
Top Stories
From the President: Nurturing the Next Generation of ID Physicians and Scientists
Updated IDSA/ESCMID Guideline for Uncomplicated Cystitis
IDSA Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.